Plain-English translation of NCT06349317 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new approach for a serious type of liver cancer: combining radiation therapy with two medications — camrelizumab and apatinib — before surgery. The goal is to shrink the cancer and make surgery more effective, especially when the cancer has invaded the blood vessels that drain the liver.
When liver cancer grows into the portal vein (the major blood vessel draining the liver), it becomes much harder to treat and patients have fewer options. This trial explores whether giving this medication combination and radiation before surgery can improve outcomes and help more patients survive longer.
You likely qualify if…
You likely don't qualify if…
You would receive radiation therapy targeting your liver cancer, combined with two medications given by injection or pills, typically given over several weeks before surgery. You'll have regular clinic visits for blood tests, imaging scans, and possibly biopsies to monitor how the treatment is working. Once the pre-treatment phase is complete, you would have surgery to remove the cancer. Throughout the study, you'll be monitored for side effects and treatment response.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
China